Persistence of severe global inequalities in the burden of Hypertension Heart Disease from 1990 to 2019: findings from the global burden of disease study 2019

M Lu, D Li, Y Hu, L Zhang, Y Li, Z Zhang, C Li - BMC Public Health, 2024 - Springer
Aims Assessing the global burden and health inequalities of Hypertension Heart Disease
(HHD) during the period from 1990 to 2019. Methods Secondary analysis of the Global …

Cardiovascular disease, diabetes mellitus, and hypertension in Lewy body disease: A comparison with other dementia disorders

K Javanshiri, M Haglund… - Journal of Alzheimer's …, 2019 - content.iospress.com
Background: Research concerning the potential roles of cardiovascular disease (CaVD) and
diabetes mellitus (DM) as risk factors for Lewy body disease (LBD) is limited. These …

Trends by age and sex and projections of disease prevalence from studying hypertensive heart disease in China over the past three decades

Y Su, H He, J Yang, Y Liu, W Jiang, C Li… - … Journal of Health …, 2024 - Wiley Online Library
Background Hypertensive heart disease (HHD) is a common cause of cardiovascular
disease and mortality worldwide, and its burden is increasing with aging populations …

[HTML][HTML] Anatomy, thorax, heart muscles

DB Tran, C Weber, RA Lopez - 2019 - europepmc.org
The heart muscle is the myocardium or middle layer of the heart walls. The myocardium is
responsible for the contractile function of the cardiac pump. Composed of cardiomyocytes …

[HTML][HTML] The prevalence, disability-adjusted life years, and mortality of hypertensive heart disease and its attributable risk factors: results from the Global Burden …

J Qian, Y Chen, D Lu, J Ma, K Liu - Archives of Medical Science …, 2023 - ncbi.nlm.nih.gov
Results Between 1990 and 2019, the worldwide prevalence rate standardized by age
increased (EAPC= 0.17; 95% confidence interval (CI) 0.15 to 0.18), but the death rate …

Tip of the iceberg: a tertiary care centre retrospective study of left ventricular hypertrophy aetiologies

M Beneyto, E Cariou, J Brunel, A Scripcariu… - Open …, 2021 - openheart.bmj.com
Aims To phenotype patients referred to a tertiary centre for the exploration of a left ventricular
hypertrophy (LVH) starting from 12 mm of left ventricular wall thickness (LVWT). Methods …

New insights and current approaches in cardiac hypertrophy cell culture, tissue engineering models, and novel pathways involving non-coding RNA

N Kastner, K Zlabinger, A Spannbauer… - Frontiers in …, 2020 - frontiersin.org
Cardiac hypertrophy is an ongoing clinical challenge, as risk factors such as obesity,
smoking and increasing age become more widespread, which lead to an increasing …

Ankylosing spondylitis is associated with increased prevalence of left ventricular hypertrophy

H Midtbø, E Gerdts, IJ Berg, S Rollefstad… - The Journal of …, 2018 - jrheum.org
Objective. Ankylosing spondylitis (AS) is associated with increased risk for cardiovascular
disease (CVD). Left ventricular (LV) hypertrophy is a strong precursor for clinical CVD. The …

Diagnostic utility of the electrocardiographic left ventricular hypertrophy criteria in specific populations

F De la Garza Salazar, EA Rodríguez Díaz… - Acta …, 2021 - Taylor & Francis
Background Several electrocardiographic (ECG) criteria have been validated for the
diagnosis of left ventricular hypertrophy (LVH); the majority in Caucasian subjects from …

Predictors of functional improvement in the short term after MitraClip implantation in patients with secondary mitral regurgitation

MG Paulus, C Meindl, L Böhm, M Holzapfel… - Plos one, 2020 - journals.plos.org
Background and objectives MitraClip implantation is an established therapy for secondary
mitral regurgitation (MR) in high-risk patients and has shown to improve several important …